Transenterix’s (TRXC) “Buy” Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Transenterix Inc (NASDAQ:TRXC) in a report published on Monday, MarketBeat Ratings reports. The firm currently has a $4.00 price target on the stock, up from their prior price target of $3.75.

A number of other brokerages have also weighed in on TRXC. Ladenburg Thalmann Financial Services set a $5.00 price target on shares of Transenterix and gave the company a buy rating in a report on Friday, October 20th. Zacks Investment Research upgraded shares of Transenterix from a hold rating to a buy rating and set a $0.75 price target on the stock in a report on Thursday, July 13th.

ILLEGAL ACTIVITY WARNING: This story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/02/transenterixs-trxc-buy-rating-reiterated-at-stifel-nicolaus.html.

In related news, insider Todd Pope sold 600,000 shares of Transenterix stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total transaction of $2,208,000.00. Following the transaction, the insider now owns 462,644 shares in the company, valued at approximately $1,702,529.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Several large investors have recently bought and sold shares of the stock. Sabby Management LLC acquired a new position in shares of Transenterix during the 2nd quarter valued at $2,456,000. Goldman Sachs Group Inc. lifted its holdings in shares of Transenterix by 7,137.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock valued at $854,000 after acquiring an additional 1,186,575 shares in the last quarter. UBS Oconnor LLC acquired a new position in shares of Transenterix during the 2nd quarter valued at $390,000. Royal Bank of Canada lifted its holdings in shares of Transenterix by 17.1% during the 2nd quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock valued at $298,000 after acquiring an additional 61,034 shares in the last quarter. Finally, Global X Management Co. LLC lifted its holdings in shares of Transenterix by 238.3% during the 2nd quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock valued at $235,000 after acquiring an additional 233,213 shares in the last quarter.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply